ZANIDATAMAB ZOVODOTIN
UNII HKH2GV9PVO

Substance Identification & Data

This profile provides standardized clinical and technical data for Zanidatamab Zovodotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) HKH2GV9PVO.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2329698-82-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
HKH2GV9PVO
CAS Registry Number
2329698-82-8
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
ZANIDATAMAB ZOVODOTIN
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C175879
National Cancer Institute reference terminology for clinical and research data.
INN ID
11433
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
protein
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Zanidatamab Zovodotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

ZANIDATAMAB ZOVODOTIN

Common Names & Synonyms

IMMUNOGLOBULIN G1, ANTI-(HUMAN TYROSINE KINASE RECEPTOR HER2) (HUMAN-MUS MUSCULUS BIPARATOPIC MONOCLONAL ZW25 LIGHT CHAIN VARIABLE REGION FRAGMENT) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 20-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN-MUS MUSCULUS BIPARATOPIC MONOCLONAL ZW25 HEAVY CHAIN VARIABLE REGION FRAGMENT FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 2-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN FC FRAGMENT, (261->229'),(264->232')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN TYROSINE KINASE RECEPTOR HER2) (HUMAN-MUS MUSCULUS BIPARATOPIC MONOCLONAL ZW25 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS BIPARATOPIC MONOCLONAL ZW25 .KAPPA.-CHAIN, REDUCED, THIOETHER WITH N-(3-(2-(2-(2-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)ETHOXY)ETHOXY)ETHOXY)-1-OXOPROPYL)-L-VALYL-N5-(AMINOCARBONYL)-N-(4-((((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N,N-DIMETHYL-L-VALYL-L-VALYL)METHYLAMINO)-3-METHOXY-5-METHYL-1-OXOHEPTYL)-2-PYRROLIDINYL)-3-METHOXY-2-METHYL-1-OXOPROPYL)AMINO)SULFONYL)PHENYL)-L-ORNITHINAMIDE
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINE PROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPPING EPITOPES ON ERBB2, ON EXTRACELLULAR DOMAINS 2 (ECD2) AND 4 (ECD4), RESPECTIVELY), CONJUGATED TO AURISTATIN E
ZANIDATAMAB ZOVODOTIN [INN]
ZW 49 [WHO-DD]

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus